Please use this identifier to cite or link to this item:
http://repository.kln.ac.lk/handle/123456789/27941
Title: | A global survey on the use of the international classification of diseases codes for metabolic dysfunction-associated fatty liver disease |
Authors: | Zhang, H. Targher, G. Byrne, C.D. Kim, S.U. Wong, V.W. Valenti, L. Glickman, M. Ponce, J. Mantzoros, C.S. Crespo, J. Gronbaek, H. Yang, W. Eslam, M. Wong, R.J. Machado, M.V. Yu, M. Ghanem, O.M. Okanoue, T. Liu, J. Lee, Y. Xu, X. Pan, Q. Sui, M. Lonardo, A. Yilmaz, Y. Zhu, L. Moreno, C. Miele, L. Lupsor-Platon, M. Zhao, L. LaMasters, T.L. Gish, R.G. Zhang, H. Nedelcu, M. Chan, W.K. Xia, M. Bril, F. Shi, J. Datz, C. Romeo, S. Sun, J. Liu, D. Sookoian, S. Mao, Y. Méndez-Sánchez, N. Wang, X. Pyrsopoulos, N.T. Fan, J. Fouad, Y. Sun, D. Giannini, C. Chai, J. Xia, Z. Jun, D.W. Li, G. Treeprasertsuk, S. Li, Y. Cheung, T.T. Zhang, F. Goh, G.B. Furuhashi, M. Seto, W. Huang, H. Sessa, A.D. Li, Q. Cholongitas, E. Zhang, L. Silveira, T.R. Sebastiani, G. Adams, L.A. Chen, W. Qi, X. Rankovic, I. Ledinghen, V.D. Lv, W. Hamaguchi, M. Kassir, R. Müller-Wieland, D. Romero-Gomez, M. Xu, Y. Xu, Y. Chen, S. Kermansaravi, M. Kuchay, M.S. Lefere, S. Parmar, C. Lip, G.Y.H. Liu, C. Åberg, F. Lau, G. George, J. Sarin, S.K. Zhou, J. Zheng, M. Niriella, M.A. (MAFLD ICD-11 coding collaborators) |
Keywords: | Global survey ICD-11 MAFLD |
Issue Date: | 2024 |
Publisher: | Springer |
Citation: | Hepatology International. 2024(Online ahead of print) |
Abstract: | BACKGROUND With the implementation of the 11th edition of the International Classification of Diseases (ICD-11) and the publication of the metabolic dysfunction-associated fatty liver disease (MAFLD) nomenclature in 2020, it is important to establish consensus for the coding of MAFLD in ICD-11. This will inform subsequent revisions of ICD-11.METHODS Using the Qualtrics XM and WJX platforms, questionnaires were sent online to MAFLD-ICD-11 coding collaborators, authors of papers, and relevant association members.RESULTS A total of 890 international experts in various fields from 61 countries responded to the survey. We also achieved full coverage of provincial-level administrative regions in China. 77.1% of respondents agreed that MAFLD should be represented in ICD-11 by updating NAFLD, with no significant regional differences (77.3% in Asia and 76.6% in non-Asia, p = 0.819). Over 80% of respondents agreed or somewhat agreed with the need to assign specific codes for progressive stages of MAFLD (i.e. steatohepatitis) (92.2%), MAFLD combined with comorbidities (84.1%), or MAFLD subtypes (i.e., lean, overweight/obese, and diabetic) (86.1%).CONCLUSIONS This global survey by a collaborative panel of clinical, coding, health management and policy experts, indicates agreement that MAFLD should be coded in ICD-11. The data serves as a foundation for corresponding adjustments in the ICD-11 revision. |
Description: | Indexed in MEDLINE. |
URI: | http://repository.kln.ac.lk/handle/123456789/27941 |
ISSN: | 1936-0533 (Print) 1936-0541 (Electronic) |
Appears in Collections: | Journal/Magazine Articles |
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.